GSK Plunges 5.37% Amid Legal Concerns, Buyback Program

On April 7, 2025, GSK's stock experienced a significant drop of 5.37% in pre-market trading, reflecting investor concerns and market sentiment.

GSK has recently announced a share buyback program, repurchasing 808,000 of its ordinary shares. This move is part of the company's ongoing efforts to enhance shareholder value and demonstrate confidence in its financial health.

Investors have been closely monitoring GSK's legal developments, as a class action securities lawsuit has been filed against the company. This lawsuit aims to recover losses incurred by shareholders due to alleged false or misleading statements and omissions of material information.

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GSK, setting a price target of £14.50. This rating reflects the analyst's assessment of the company's current performance and future prospects, providing guidance for investors considering GSK's stock.